KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections.

Zhiqiang Li, Yue Kang, Hongqiang Gao, Yingpeng Zhao, Ding Luo, Dongdong Wang, Xiang Zhang, Jieqi Yu, Guang Chu, Jun Cao, Fan Wang, Xiongqi Zhao, Erin Jensen, Gina Lin, Gang Chen

Infect Dis (Lond) 58(1) 40-51

PMID40913503
PMCID-
DOI10.1080/23744235.2025.2544828
发表日期2025-09-06
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Ceftolozane/tazobactam (C/T) in combination with metronidazole is an active antimicrobial therapy used to treat complicated intra-abdominal infections (cIAIs). METHODS: A comparison of the clinical efficacy of C/T plus metronidazole vs. meropenem for the treatment of cIAIs using pooled data from four phase 3 clinical studies (CXA-cIAI-10-08, CXA-cIAI-10-09, NCT02739997 and NCT03830333). RESULTS: In total, 1,361 patients (C/T plus metronidazole, n = 721; meropenem, n = 640) were included in the pooled analysis. Clinical response rates at the test of cure (TOC) visit in the intention-to-treat (ITT) and clinically evaluable populations were 84.3% (608/721) and 86.9% (556/640) as well as 93.4% (534/572) and 93.8% (483/515), and at the end of treatment visits the rates were 90.6% (653/721) and 91.9% (588/640) as well as 96.5% (552/572) and 96.6% (499/515) for C/T plus metronidazole and meropenem, respectively. Microbiological response rates at the TOC visits in the modified ITT population were 85.3% (440/516) and 89.3% (442/495), and in the extended microbiological evaluable population 93.7% (399/426) and 94.3% (394/418) for C/T plus metronidazole and meropenem, respectively. Adverse events occurred in 341/716 (47.6%) and 280/631 (44.4%) patients treated with C/T plus metronidazole and meropenem, respectively. The most common adverse events across treatment groups were diarrhoea, nausea, pyrexia and insomnia. No new serious safety findings were identified. CONCLUSIONS: The efficacy of C/T plus metronidazole was comparable with meropenem even for cIAIs and C/T plus metronidazole might be an alternative treatment option for cIAI.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。